Ibandronate: New options in the treatment of osteoporosis

Drugs of Today

Volumn 39, Issue 11, 2003, Pages 877-886

  Adami, Silvano ^a   Viapiana, O ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CORTICOSTEROID; IBANDRONIC ACID; NERIDRONIC ACID; OLPADRONIC ACID; PAMIDRONIC ACID; RALOXIFENE; RISEDRONIC ACID; ZOLEDRONIC ACID;

ACUTE KIDNEY FAILURE; CLINICAL TRIAL; CONTINUOUS INFUSION; CORTICOSTEROID INDUCED OSTEOPOROSIS; DRUG ABSORPTION; DRUG DOSE REGIMEN; DRUG POTENCY; DRUG STRUCTURE; DRUG TOLERABILITY; DYSPEPSIA; ESOPHAGUS DISEASE; FEMALE; FOOD DRUG INTERACTION; FRAGILITY FRACTURE; HEADACHE; HUMAN; INFECTION; INTESTINE ABSORPTION; LEUKOCYTOSIS; LYMPHOCYTOPENIA; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; THROMBOSIS;

ADMINISTRATION, ORAL; DIPHOSPHONATES; DISEASE MANAGEMENT; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; OSTEOPOROSIS;

EID: 0346457041     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2003.39.11.799465     Document Type: Review

References (49)

1. Harris, S.T., Watts, N.B., Jackson, R.D. et al. Four year-study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: Three years of blinded therapy followed by one year of open therapy. Am J Med 1993, 95: 557-67.
2. McCloskey, E., Selby, P., De Takats, D. et al. Effects of clodronate on vertebral fracture risk in osteoporosis: A 1 year interim analysis. Bone 2001, 28: 310-5.
3. Reginster, J.Y., Deroisy, R., Denis, D. et al. Prevention of postmenopausal bone loss by tiludronate. Lancet 1989, ii: 1469-71.
4. Black, D.M., Cummings, S.R., Karpf, D.B. et al. Randomized trial of effect of alendronate on risk fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 1996, 348: 1535-1541.
5. Reginster, J.Y., Minne, H.W., Sorensen, O.H. et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000, 11: 83-91.
6. Harris, S.T., Watts, N.B., Genant H.K. et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: A randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999, 282: 1344-52.
7. Ettinger, B., Black, D.M., Mitlak, B.H. et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: Results from a 3-year randomized clinical trial. JAMA 1999, 282: 637-645.
8. Fleisch, H.A. Bisphosphonates: Preclinical aspects and use in osteoporosis. Ann Med 1997, 29: 55-62.
9. Schnitzer, T., Bone, H.G., Crepaldi, G. et al. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Aging Clin Exp Res 2000, 12: 1-12.
10. Brown, J.P., Kendler, D.L., McClung, M.R. et al. The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis. Calcif Tissue Int 2002, 71: 103-11.
11. Bounameaux, H.M., Schifferli, J., Montani, J.P., Jung, A., Chatelanat, F. Renal failure associated with intravenous diphosphonates. Lancet 1983, 1: 471.
12. Dumon, J.C., Magritte, A., Body, J.J. Efficacy and safety of the bisphosphonate tiludronate for the treatment of tumor-associated hypercalcemia. Bone Miner 1991, 15: 257-66.
13. Adami, S., Zamberlan, N. Adverse effects of bisphosphonates: A comparative review. Drug Safety 1996, 14: 158-70.
14. Pecherstorfer, M., Ludwig, H., Schlosser, K., Buck, S., Huss, H.J., Body, J.J. Administration of the bisphosphonate ibandronate (BM 21.0955) by intravenous bolus injection. J Bone Miner Res 1996, 11: 587-93.
15. Ravn, P., Neugebauer, G., Christiansen, C. Association between pharmacokinetics of oral ibandronate and clinical response in bone mass and bone turnover in women with postmenopausal osteoporosis. Bone 2002, 30: 320-4.
16. Rogers, M.J., Xiong, X., Brown, R.J. et al. Structure-activity relationships of new heterocycle-containing bisphosphonates as inhibitors of bone resorption and as inhibitors of growth of Dictyostelium discoideum amoebae. Mol Pharmacol 1995, 47: 398-402.
17. Van Beek, E.R., Lowik, C.W., Ebetino, F.H., Papapoulos, S.E. Binding and antiresorptive properties of heterocycle-containing bisphosphonates analogs: Structure-activity relationships. Bone 1998, 23: 437-42.
18. Van Beek, E., Pieterman, E., Cohen, L., Lowik, C., Papapoulos, S. Nitrogen-containing bisphosphonates inhibit isopentenyl pyrophosphate isomerase/farnesyl pyrophosphate synthase activity with relative potencies corresponding to their antiresorptive potencies in vitro and in vivo. Biochem Biophys Res Commun 1998, 255: 491-4.
19. Geddes, A.D., D'Souza, S.M., Ebetino, F.H. et al. Bisphosphonates: Structure-activity relationship and therapeutic implication. In: Bone and Mineral Research. Heersche, J.N.M., Kanis, J.A. (Eds.). Elsevier Publishing Co., Amsterdam 1994, 265-306.
20. Rogers, M.J., Gordon, S., Benford, H.L. et al. Cellular and molecular mechanisms of action of bisphosphonates. Cancer 2000, 88: 2961-78.
21. Green, J.R., Muller, K., Jaeggi, K.A. Preclinical pharmacology of CGP 42'446, a new, potent, heterocyclic bisphosphonates compound. J Bone Miner Res 1994, 9: 745-51.
22. Dunford, J.E., Thompson, K., Coxon, F.P. et al. Structure-activity relatioship for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J Pharmacol Exp Ther 2001, 296: 235-42.
23. 45Ca kinetics in the intact rat. Osteoporos Int 1996, 6: 166-70.
24. Monier-Faugere, M.C., Friedler, R.M., Bauss, F., Malluche, H.H. A new bisphosphonate, BM-21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J Bone Miner Res 1993, 11: 1345-1355.
25. Monier-Faugere, M.C., Geng, Z., Paschalis, E.P. et al. Intermittent and continuous administration of the bisphosphonates ibandronate in ovario-hysterectomized beagle dogs: Effect on bone morphometry and mineral properties. J Bone Miner Res 1999, 14: 1768-78.
26. Lalla, S., Hothorn, L.A., Haag, N., Bader, R., Bauss, F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteopor Int 1998, 8: 97-103.
27. Bauss, F., Wagner, M., Hothorn, L.H. Total administeres dose of ibandronate determines effects on bone mass and architecture in ovariectomized aged rats. J Rheumatol 2002, 29: 990-8.
28. Investigator's Brochure Ro 200-5450. Ibandronate (BM 21.0955). Roche 2001.
29. Rizzoli, R., Thiebaud, D., Bundred, N. et al. Serum parathyroid hormone-related protein levels and response to bisphosphonate treatment in hypercalcemia of malignancy. J Clin Endocrinol Metab 1999, 84: 3545-50.
30. Pecherstorfer, M., Herrmann, Z., Body, J.J. et al. Randomized phase II trial comparing different doses of the bisphosphonate ibandronate in the treatment of hypercalcemia of malignancy. J Clin Oncol 1996, 14: 268-76.
31. Menssen, H.D., Sakalova, A., Fontana, A. et al. Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma. J Clin Oncol 2002, 20: 2353-9.
32. Coleman, R.E., Purohit, O.P., Black, C. et al. Double-blind, randomized, placebo-controlled, dose-finding study of oral ibandronate in patients with metastatic bone disease. Ann Oncol 1999, 10: 311-6.
33. Woitge, H.W., Oberwittler, H., Heichel, S., Grauer, A., Ziegler, R. Seibel, M.J. Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin Chem 2000, 46: 684-90.
34. Grauer, A., Heichel, S., Knaus, J., Dosch, E., Ziegler, R. Ibandronate treatment in Paget's disease of bone. Bone 1999, 24: 87S-89S.
35. Tanko', L.B., McClung, M.R., Schimmer, R.C., Mahoney, P., Christiansen, C. The efficacy of 48-week oral ibandronate treatment in postmenopausal osteoporosis when taken 30 versus 60 minutes before breakfast. Bone 2003, 32: 421-6.
36. Adami, S., Bhalla, A.K., Dorizzi, R. et al. The acute-phase response after bisphosphonates administration. Calcif Tissue Int 1987, 41: 326-31.
37. Ravn, P., Clemmesen, B., Riis, B.J., Christiansen, C. The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonates for prevention and treatment of postmenopausal osteoporosis: A 1 year, randomised, double-blind, placebo-controlled dose-finding study. Bone 1996, 19: 527-33.
38. Riis, B.J., Ise, J., Von Stein, T., Bagger, Y., Christiansen, C. Ibandronate: A comparison of oral daily dosing versus intermittent dosing in postmenopausal osteoporosis. J Bone Miner Res 2001, 16: 1871-8.
39. Delmas, P.D., Chesnut III, C.H., Christiansen, C. et al. Daily and intermittent oral ibandronate provide significant reductions in vertebral fracture risk: Results from a large phase III study. Calcif Tissue Int 2003, 72: O-44.
40. Recker, R.R., Stakkestad, J.A., Weber, T. et al. Non-vertebral fracture benefit from oral ibandronate administered daily or with a unique drug-free interval: Results from a pivotal phase III study in postmenopausal osteoporosis (PMO). 24th ASBMR (September 20-24, San Antonio, Texas). J Bone Miner Res 2002, 17: S 134 Abstr. 1038.
41. Delmas, P.D., Skag, A., Chesnut III, C.H. et al. Upper gastrointestinal safety profile of oral daily and intermittent ibandronate: Results from a large pivotal phase III study. 3rd International Meeting on Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (November 6-9, Barcelona). Osteoporos Int 2002, 13: S15 Abstr. O16.
42. Cooper, C., Hawker, G., Emkey, R. et al. Efficacy and safety of oral weekly ibandronate in the treatment of postmenopausal osteoporosis (PMO). 24th ASBMR (September 20-24, San Antonio, Texas). J Bone Miner Res 2002, 17: S206 Abstr. F339.
43. McClung, M., Wasnich, R.D., Recker, R. et al. Daily oral ibandronate prevents bone loss in postmenopausal women without osteoporosis. 24th ASBMR (September 20-24, San Antonio, Texas). J Bone Miner Res 2002, 17: S157 Abstr. 1138.
44. Felsenberg, D., Christiansen, C., Cerwinski, E., Burdeska, A., Jonkanski, I., Meinert, R. Weekly dosing of oral ibandronate is effective in the prevention of postmenopausal osteoporosis. Osteoporos Int 2002, 13 (Suppl. 1): S16-7.
45. Thiebaud, D., Burckhardt, P., Kriegbaum, H. et al. Three monthly intravenous injections of ibandronate in the treatment of postmenopausal osteoporosis. Am J Med 1997, 103: 298-307.
46. Recker, R.R., Stakkestad, J.A., Felsenberg, D. et al. A new treatment paradigm: Quarterly injections of ibandronate reduce the risk of fractures in women with postmenopausal osteoporosis (PMO): Results of a 3-year trial. Osteoporos Int 2000, 11: S209.
47. Adami, S., Christiansen, C., Burdeska, R., Coutant, K., Mahoney, P. Three-monthly 2 mg intravenous ibandronate injections restore bone turnover to premenopausal levels. 24th ASBMR (September 20-24, San Antonio, Texas). J Bone Miner Res 2002, 17: S472 Abstr. M347.
48. Liberman, U.A., Stuart, P.D., Weiss, M.D. et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 1995, 333: 1437-43.
49. Cummings, S.R., Black, D.M., Desmond, E. et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. Results from the Fracture Intervention Trial. JAMA 1998, 280: 2077-82.